Anzeige
Mehr »
Login
Sonntag, 19.09.2021 Börsentäglich über 12.000 News von 674 internationalen Medien
Rennen um begehrtesten KLIMA-ROHSTOFF beginnt! Holt sich Nobel Resources die Pole-Position?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A116Z9 ISIN: BMG570071099 Ticker-Symbol: LUP 
Frankfurt
17.09.21
08:06 Uhr
0,442 Euro
+0,016
+3,76 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
LUYE PHARMA GROUP LTD Chart 1 Jahr
5-Tage-Chart
LUYE PHARMA GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,4360,45018.09.

Aktuelle News zur LUYE PHARMA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrLuye Pharma Group: Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi Arabia213JEDDAH, Saudi Arabia, Sept. 17, 2021 /PRNewswire/ -- Luye Pharma Group has recently been granted official approval by the Saudi Food and Drug Authority to become the Marketing Authorization...
► Artikel lesen
LUYE PHARMA Aktie jetzt für 0€ handeln
DoLuye Pharma enters into an agreement with ESTEVE to commercialize an Alzheimer's Disease Multi-Day Treatment Patch in Spain285BASEL, Switzerland, Sept. 16, 2021 /PRNewswire/ -- Luye Pharma Switzerland AG ("Luye Switzerland"), a fully owned subsidiary of Luye Pharma Group (Luye Pharma), and Esteve Pharmaceuticals...
► Artikel lesen
MoLUYE PHARMA (02186): DISCLOSEABLE TRANSACTION - THIRD PARTIES' INVESTMENTS IN BOAN BIOTECH-
09.09.Luye Pharma (02186) signs agreement with ESTEVE1
08.09.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - LUYE PHARMA GRANTS EXCLUSIVE RIGHTS TO COMMERCIALIZE NEW DRUG RIVASTIGMINE MD IN SPAIN TO ESTEVE-
08.09.CS lowers Luye Pharma (02186) to HK$4.81
06.09.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - GOSERELIN ACETATE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY01005) COMPLETED PHASE III CLINICAL TRIAL ...1
26.08.LUYE PHARMA (02186): DISCLOSEABLE TRANSACTION - THIRD PARTIES INVESTMENTS IN BOAN BIOTECH1
23.08.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - NEW INDICATION APPROVED FOR BOYOUNUO (BEVACIZUMAB INJECTION) IN CHINA2
20.08.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - UPDATED PROGRESS IN RELATION TO NEUTRALIZING ANTIBODY AGAINST SARS-COV-2-
17.08.LUYE PHARMA (02186): NOTICE OF BOARD MEETING1
02.08.Luye Pharma (02186) submits IND application to FDA2
02.08.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION SUBMITTED IN THE U.S. FOR THE GROUP'S NEW DRUG LY030154
28.07.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - NEW INDICATION APPROVED FOR BOYOUNUO (BEVACIZUMAB INJECTION) IN CHINA3
22.07.LUYE PHARMA (02186): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 20202
02.07.Luye Pharma (02186) submits spin-off of Boan Biotech4
02.07.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - PROPOSED SPIN-OFF AND SEPARATE LISTING OF BOAN BIOTECH4
16.06.LUYE PHARMA (02186): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 16 JUNE 20212
15.06.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL APPLICATION SUBMITTED IN THE U.S. FOR NEUTRALIZING ANTIBODY AGAINST SARS-COV-22
11.06.Luye Pharma (02186) gets marketing authorization application3
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1